Last reviewed · How we verify
Triptergium Wilfordii
Triptergium wilfordii extract suppresses immune cell activation and reduces inflammatory cytokine production through multiple pathways including NF-κB inhibition.
Triptergium wilfordii extract suppresses immune cell activation and reduces inflammatory cytokine production through multiple pathways including NF-κB inhibition. Used for Rheumatoid arthritis, Systemic lupus erythematosus, Nephrotic syndrome.
At a glance
| Generic name | Triptergium Wilfordii |
|---|---|
| Sponsor | Ministry of Health, China |
| Drug class | Herbal immunosuppressant |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The plant extract contains multiple bioactive compounds (triptolide and other diterpenoids) that inhibit T cell proliferation, reduce pro-inflammatory cytokine secretion (TNF-α, IL-2, IL-6), and modulate immune responses. It acts as a broad immunosuppressant and anti-inflammatory agent, making it useful in autoimmune and inflammatory conditions.
Approved indications
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Nephrotic syndrome
- Other autoimmune and inflammatory diseases
Common side effects
- Gastrointestinal disturbance
- Hepatotoxicity
- Bone marrow suppression
- Reproductive toxicity
- Amenorrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triptergium Wilfordii CI brief — competitive landscape report
- Triptergium Wilfordii updates RSS · CI watch RSS
- Ministry of Health, China portfolio CI